Sean Wharton, MD, PharmD: Abbvie: Advisory Board (); Amgen: Academic Talks to Colleagues (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); AstraZeneca: Academic Talks to Colleagues (), Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Bausch Health Canada: Academic Talks to Colleagues (), Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Boehringer Ingelheim: Academic Talks to Colleagues (), Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Eli Lilly & Company: Academic Talks to Colleagues (), Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); I20 Therapeutics: Advisory Board (); Merck: Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Metsera: Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); NGX: Advisory Board (); Novo Nordisk: Academic Talks to Colleagues (), Advisory Board (), Clinical Trial Investigator (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Regeneron: Advisory Board (); York University: Clinical Trial Investigator ()
Recent advances in obesity pharmacotherapy are transforming metabolic care through increasingly potent and diverse mechanisms of action. This session will explore next-generation injectable incretin-based agents, including dual and triple receptor agonists; oral and nonpeptide anti-obesity medications designed to improve accessibility, adherence, and long-term weight maintenance; and emerging pathways beyond gut hormones that may redefine how obesity and metabolic diseases are treated. Speakers will integrate preclinical and clinical insights to highlight innovation in drug design, efficacy, and durability—offering a forward-looking view of the evolving therapeutic landscape for obesity.
Learning Objectives:
Summarize the mechanisms and clinical outcomes of dual and triple incretin receptor agonists under development for obesity and metabolic disease.
Evaluate the potential of oral and nonpeptide therapies to improve patient adherence, access, and treatment durability.
Identify novel non-incretin molecular targets and pathways that may expand future therapeutic options for obesity management.
